Related Experiment Video
Updated: Oct 31, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Multiparametric Implantable Cardioverter-Defibrillator Algorithm for Heart Failure Risk Stratification and
Leonardo Calò1, Valter Bianchi2, Donatella Ferraioli3
1Cardiology Department, Policlinico Casilino, Rome, Italy (L.C., E.D.R.).
Insights
The HeartLogic algorithm effectively identifies patients at high risk for heart failure (HF) events. Clinical actions taken in response to HeartLogic alerts were associated with a significant reduction in HF events.
Area of Science:
- Cardiology
- Biomedical Engineering
- Medical Device Technology
Background:
- Heart failure (HF) poses a significant clinical challenge.
- Early detection of HF events is crucial for timely intervention.
- Implantable cardioverter-defibrillators (ICDs) offer advanced monitoring capabilities.
Purpose of the Study:
- To evaluate the HeartLogic algorithm's risk stratification accuracy for heart failure events in clinical practice.
- To analyze the impact of alert management strategies on heart failure event occurrence.
Main Methods:
- The HeartLogic algorithm was activated in 366 patients with ICDs or cardiac resynchronization therapy-ICDs across 22 centers.
- Patients were monitored for a median of 11 months.
- HeartLogic daily HF index and alert states were analyzed in relation to HF events.
Main Results:
- The HeartLogic algorithm identified increased HF risk periods in 150 patients.
- Patients in an alert state had a significantly higher risk of HF events (HR, 24.53; P<0.001).
- Clinical actions following alerts correlated with fewer HF events (HR, 0.37; P=0.047).
Conclusions:
- The HeartLogic algorithm effectively identifies patients at heightened risk for heart failure events.
- Prompt clinical response to HeartLogic alerts may reduce HF event rates.
- Effective alert management does not necessitate additional in-office visits.
Background:
The HeartLogic algorithm combines multiple implantable cardioverter-defibrillator sensors to identify patients at risk of heart failure (HF) events. We sought to evaluate the risk stratification ability of this algorithm in clinical practice. We also analyzed the alert management strategies adopted in the study group and their association with the occurrence of HF events.
Methods:
The HeartLogic feature was activated in 366 implantable cardioverter-defibrillator and cardiac resynchronization therapy implantable cardioverter-defibrillator patients at 22 centers. The median follow-up was 11 months [25th-75th percentile: 6-16]. The HeartLogic algorithm calculates a daily HF index and identifies periods IN alert state on the basis of a configurable threshold.
Results:
The HeartLogic index crossed the threshold value 273 times (0.76 alerts/patient-year) in 150 patients. The time IN alert state was 11% of the total observation period. Patients experienced 36 HF hospitalizations, and 8 patients died of HF during the observation period. Thirty-five events were associated with the IN alert state (0.92 events/patient-year versus 0.03 events/patient-year in the OUT of alert state). The hazard ratio in the IN/OUT of alert state comparison was (hazard ratio, 24.53 [95% CI, 8.55-70.38], P<0.001), after adjustment for baseline clinical confounders. Alerts followed by clinical actions were associated with less HF events (hazard ratio, 0.37 [95% CI, 0.14-0.99], P=0.047). No differences in event rates were observed between in-office and remote alert management.
Conclusions:
This multiparametric algorithm identifies patients during periods of significantly increased risk of HF events. The rate of HF events seemed lower when clinical actions were undertaken in response to alerts. Extra in-office visits did not seem to be required to effectively manage HeartLogic alerts. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02275637.
More Related Videos
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Cardiomyopathy III: Hypertrophic Cardiomyopathy

